US2023235060A1PendingUtilityA1

Neutralization of inhibitory pathways in lymphocytes

Assignee: INNATE PHARMAPriority: Sep 16, 2014Filed: Feb 6, 2023Published: Jul 27, 2023

Est. expirySep 16, 2034(~8.1 yrs left)· nominal 20-yr term from priority

Inventors:Pascale Andre Mathieu Blery Carine Paturel Nicolai Wagtmann

C07K 16/2818C07K 16/2803C07K 16/2827A61K 39/39558C07K 16/30A61K 2039/507A61K 39/395C07K 2317/76A61P 1/00A61P 11/00A61P 13/12A61P 15/00A61P 17/00A61P 35/00A61P 35/02A61P 43/00A61K 2300/00C07K 2317/24A61K 2039/545C07K 2317/565

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

Claims

exact text as granted — not AI-modified

We claim: 
     
         1 . An in vitro method for detecting a NKG2A + PD-1 +  lymphocyte, optionally an NK or CD8 +  T cell, comprising providing a biological sample comprising tumor infiltrating lymphocytes and determining whether the lymphocytes express NKG2A and PD-1. 
     
     
         2 . An in vitro method for modulating the activity of NKG2A + PD-1 +  lymphocytes, optionally CD8 +  T cells, comprising bringing lymphocytes expressing at their surface NKG2A and PD-1 into contact with an antibody that neutralizes the inhibitory activity of NKG2A and an antibody that neutralizes the inhibitory activity of PD-1.

Join the waitlist — get patent alerts

Track US2023235060A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.